MA37670A1 - Anticorps anti-transglutaminase 2 - Google Patents

Anticorps anti-transglutaminase 2

Info

Publication number
MA37670A1
MA37670A1 MA37670A MA37670A MA37670A1 MA 37670 A1 MA37670 A1 MA 37670A1 MA 37670 A MA37670 A MA 37670A MA 37670 A MA37670 A MA 37670A MA 37670 A1 MA37670 A1 MA 37670A1
Authority
MA
Morocco
Prior art keywords
central region
transglutaminase
antibody
antibodies
diseases
Prior art date
Application number
MA37670A
Other languages
Arabic (ar)
English (en)
Other versions
MA37670B1 (fr
Inventor
Tim Johnson
Phil Watson
David Matthews
Alex Brown
Original Assignee
Medical Research Council Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46546551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37670(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical Research Council Tech filed Critical Medical Research Council Tech
Publication of MA37670A1 publication Critical patent/MA37670A1/fr
Publication of MA37670B1 publication Critical patent/MA37670B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)

Abstract

L'invention concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci, qui se lient sélectivement à un épitope dans la région centrale de la transglutaminase de type 2 (tg2). De nouveaux épitopes dans la région centrale de tg2 sont décrits. L'invention concerne des anticorps inhibant la tg2 humaine et leurs utilisations, notamment en médecine, par exemple pour le traitement et/ou le diagnostic de troubles tels que la maladie cœliaque, la formation de cicatrices, les maladies liées à la fibrose, les maladies neurodégénératives/neurologiques et le cancer.
MA37670A 2012-05-24 2013-05-24 Anticorps anti-transglutaminase 2 MA37670B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1209096.5A GB201209096D0 (en) 2012-05-24 2012-05-24 Compounds
PCT/GB2013/051373 WO2013175229A1 (fr) 2012-05-24 2013-05-24 Anticorps anti-transglutaminase 2

Publications (2)

Publication Number Publication Date
MA37670A1 true MA37670A1 (fr) 2016-05-31
MA37670B1 MA37670B1 (fr) 2019-12-31

Family

ID=46546551

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37670A MA37670B1 (fr) 2012-05-24 2013-05-24 Anticorps anti-transglutaminase 2

Country Status (39)

Country Link
US (3) US10005846B2 (fr)
EP (2) EP2855530B1 (fr)
JP (2) JP6411998B2 (fr)
KR (1) KR102091223B1 (fr)
CN (1) CN104321346B (fr)
AU (1) AU2013265025B2 (fr)
BR (1) BR112014029089B1 (fr)
CA (1) CA2874488C (fr)
CL (1) CL2014003125A1 (fr)
CO (1) CO7151528A2 (fr)
CY (2) CY1121932T1 (fr)
DK (2) DK3521315T3 (fr)
EA (1) EA036810B1 (fr)
EC (1) ECSP14030942A (fr)
ES (2) ES2728856T3 (fr)
GB (1) GB201209096D0 (fr)
HR (2) HRP20191293T1 (fr)
HU (2) HUE052490T2 (fr)
IL (1) IL235369B (fr)
IN (1) IN2014MN02231A (fr)
LT (2) LT2855530T (fr)
MA (1) MA37670B1 (fr)
ME (1) ME03393B (fr)
MX (1) MX367517B (fr)
MY (1) MY185966A (fr)
NZ (1) NZ701424A (fr)
PE (1) PE20150346A1 (fr)
PH (1) PH12014502582A1 (fr)
PL (2) PL3521315T3 (fr)
PT (2) PT3521315T (fr)
RS (2) RS61286B1 (fr)
SG (1) SG11201407053YA (fr)
SI (2) SI2855530T1 (fr)
SM (2) SMT202100014T1 (fr)
TN (1) TN2014000458A1 (fr)
TR (1) TR201906781T4 (fr)
UA (1) UA117657C2 (fr)
WO (1) WO2013175229A1 (fr)
ZA (1) ZA201408213B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110055235A (zh) * 2019-05-14 2019-07-26 深圳市亚辉龙生物科技股份有限公司 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法
FR3117599B1 (fr) * 2020-12-16 2024-11-29 Oreal Méthode de pronostic et/ou de diagnostic d’un état pelliculaire du cuir chevelu
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease
CN118354792A (zh) 2021-11-18 2024-07-16 Ucb生物制药有限责任公司 用于治疗进行性慢性间质性肺部疾病的方法
GB202118010D0 (en) 2021-12-13 2022-01-26 UCB Biopharma SRL Method for detecting and/or quantifying crosslinks formed by transglutaminases
CN116515786B (zh) * 2023-04-26 2024-05-28 广东医科大学 一种人tgm3乙酰化多肽、抗原、抗体及其制备方法和应用
WO2025153465A1 (fr) * 2024-01-15 2025-07-24 UCB Biopharma SRL Procédé de traitement d'un trouble d'ordre fibrotique associé à une mii

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912120A (en) 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
AU1268192A (en) 1991-01-04 1992-08-17 Board Of Regents, The University Of Texas System Cloning and expression of tissue transglutaminases
AU6620596A (en) 1996-07-25 1998-02-20 Victoria University Of Manchester, The Use of transglutaminase modulators to promote wound healing
GB0103024D0 (en) * 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
CA2514942A1 (fr) 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Methodes et compositions de traitement de la maladie de parkinson et d'autres a-synucleinopathies
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
WO2006100679A2 (fr) * 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Anticorps de recombinaison diriges contre la transglutaminase humaine de type ii et utilisations de ces anticorps
US8299040B2 (en) 2006-10-18 2012-10-30 Board Of Regents, The University Of Texas System Methods for treating cancer targeting transglutaminase
CN102027013B (zh) * 2008-04-24 2015-01-14 株式会社遗传科技 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用
AU2010225460B2 (en) 2009-03-19 2014-05-01 Queensland University Of Technology Targets for growth factor signalling and methods of therapy
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
HU0900195D0 (en) 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis and treatment of gluten-induced autoimmune diseases
WO2011151395A2 (fr) 2010-06-02 2011-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de la transglutaminase 2 destinés être utilisés dans la prévention ou le traitement de la glomérulonéphrite maligne
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase

Also Published As

Publication number Publication date
PH12014502582B1 (en) 2015-01-21
KR102091223B1 (ko) 2020-03-20
US20210101999A1 (en) 2021-04-08
MX2014014264A (es) 2015-05-15
DK3521315T3 (da) 2020-11-09
BR112014029089A2 (pt) 2019-06-25
AU2013265025A1 (en) 2014-12-04
CA2874488A1 (fr) 2013-11-28
PE20150346A1 (es) 2015-03-05
RS61286B1 (sr) 2021-02-26
ES2728856T3 (es) 2019-10-29
EA036810B1 (ru) 2020-12-23
BR112014029089B1 (pt) 2023-04-25
PT2855530T (pt) 2019-07-08
SI2855530T1 (sl) 2019-08-30
EA201492162A1 (ru) 2015-03-31
EP2855530B1 (fr) 2019-05-01
EP2855530A1 (fr) 2015-04-08
US20150218289A1 (en) 2015-08-06
SMT202100014T1 (it) 2021-03-15
ES2835383T3 (es) 2021-06-22
HUE052490T2 (hu) 2021-04-28
US11718686B2 (en) 2023-08-08
EP3521315A1 (fr) 2019-08-07
CY1121932T1 (el) 2020-10-14
PL3521315T3 (pl) 2021-08-23
PL2855530T3 (pl) 2019-10-31
WO2013175229A1 (fr) 2013-11-28
MX367517B (es) 2019-08-26
UA117657C2 (uk) 2018-09-10
CL2014003125A1 (es) 2015-08-21
KR20150013340A (ko) 2015-02-04
PH12014502582A1 (en) 2015-01-21
JP6411998B2 (ja) 2018-10-24
TR201906781T4 (tr) 2019-05-21
CA2874488C (fr) 2021-09-07
SG11201407053YA (en) 2014-12-30
DK2855530T3 (da) 2019-06-24
NZ701424A (en) 2016-08-26
HRP20202059T1 (hr) 2021-02-19
LT3521315T (lt) 2020-12-28
IL235369B (en) 2019-05-30
ECSP14030942A (es) 2015-09-30
IL235369A0 (en) 2014-12-31
HRP20191293T1 (hr) 2019-10-18
ZA201408213B (en) 2020-02-26
CN104321346A (zh) 2015-01-28
MA37670B1 (fr) 2019-12-31
SMT201900407T1 (it) 2019-09-09
JP2015519897A (ja) 2015-07-16
CN104321346B (zh) 2018-12-07
CO7151528A2 (es) 2014-12-29
LT2855530T (lt) 2019-07-25
SI3521315T1 (sl) 2020-12-31
HK1203974A1 (en) 2015-11-06
PT3521315T (pt) 2020-10-29
GB201209096D0 (en) 2012-07-04
IN2014MN02231A (fr) 2015-07-24
ME03393B (fr) 2020-01-20
AU2013265025B2 (en) 2018-04-26
HUE045539T2 (hu) 2019-12-30
US10005846B2 (en) 2018-06-26
TN2014000458A1 (en) 2016-03-30
MY185966A (en) 2021-06-14
RS59135B1 (sr) 2019-09-30
US10961319B2 (en) 2021-03-30
EP3521315B1 (fr) 2020-10-14
CY1123926T1 (el) 2022-05-27
US20180355060A1 (en) 2018-12-13
JP2018166510A (ja) 2018-11-01

Similar Documents

Publication Publication Date Title
MA37670A1 (fr) Anticorps anti-transglutaminase 2
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
EP2987807A3 (fr) Anticorps dirigés contre tau phosphorylée
MA31886B1 (fr) Anticorps anti-hepcidine et utilisations de ceux-ci
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA30337B1 (fr) Anticorps
MA38161A1 (fr) Anticorps anti-bmp-6
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
US20220402979A1 (en) Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA44917B1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
BR112022012010A2 (pt) Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
Fei et al. Shuang-Huang-Lian prevents basophilic granulocyte activation to suppress Th2 immunity
Khare et al. Recent advances and current perspectives in treatment of Alzheimer’s disease
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
Ouyang et al. Galectin-1 serum levels reflect tumor burden and adverse clinical features in Hodgkin lymphoma
MA38159A1 (fr) Anticorps isoles qui se lient a l'antigene bcma utilises pour traiter des cancers, par exemple cancer des cellules b et myelome multiple
MA35580B1 (fr) Composition pharmaceutique
MA38502A1 (fr) Anticorps monoclonal humain isole ou son fragment de liaison a l’antigene qui se lie specifiquement a la gremlin-1 humaine utile pour le traitement des fibroses, cancers et l'inhibition de l'angiogenese